Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case–control study
Authors' conclusion
Colchicine use was associated with an increased risk of ASCVD in patients with newly diagnosed gout who did not have a prior history of ASCVD.
Study context
- Population
- Patients with incident gout without history of atherosclerotic cardiovascular disease (ASCVD) newly started on allopurinol as first-line therapy, 2011–2016, Korean National Health Insurance System; predominantly male9,346 cases · 35,070 controls
- Comparison
- Colchicine use vs non-use
- Outcome
- New ASCVD event or ASCVD-related mortality
Methodological detailsnationwide claims database, matched with four controls for age, sex, income, residential area, co-morbidities and medications
- Nationwide claims database
- Matched with four controls for age, sex, income, residential area, co-morbidities and medications
Main finding
As reported in the abstract
ASCVD event or ASCVD-related mortality
Each group vs non-usersOdds ratio (95% CI)
<90 cDDDs
1.09(1.04–1.15)
80-179 cDDDs
1.20(1.07–1.33)
≥180 cDDDs
1.21(1.09–1.35)
Observational data: associations, not effects.
Further findings
ASCVD events and ASCVD-related mortality, examined separately
- Association similarly observed for ASCVD events and ASCVD-related mortality
Original publication
Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case–control study. Rheumatology (Oxford). Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →